Alkermes to Report Third Quarter Financial Results on October 28, 2025
Alkermes (Nasdaq: ALKS) will report third quarter 2025 financial results and host a conference call and webcast on Oct 28, 2025 at 8:00 a.m. ET (12:00 p.m. GMT).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes (Nasdaq: ALKS) will report third quarter 2025 financial results and host a conference call and webcast on Oct 28, 2025 at 8:00 a.m. ET (12:00 p.m. GMT). The event will include slides available on the company's Investors website and a replay posted about two hours after the event.
Live access: U.S. dial +1 877 407 2988; international dial +1 201 389 0923. Alkermes is a global biopharmaceutical company focused on neuroscience with marketed products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline including narcolepsy and idiopathic hypersomnia. Headquarters in Ireland with R&D in Massachusetts and manufacturing in Ohio.
Details
News Market Reaction – ALKS
On Oct 21, the first trading day after this news, ALKS closed 1.52% above the previous close.
Data tracked by StockTitan Argus for the Oct 21 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-third-quarter-financial-results-on-october-28-2025-302589282.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.